NCT02322593View on ClinicalTrials.gov

Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer

PHASE3CompletedINTERVENTIONAL
Enrollment

711

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

February 28, 2019

Study Completion Date

May 31, 2020

Conditions
Gastric Cancer
Interventions
DRUG

TAS-118 plus Oxaliplatin

DRUG

S-1 plus Cisplatin

Trial Locations (6)

305-8576

Taiho Pharmaceutical Co., Ltd selected site, Ibaraki

860-8556

Taiho Pharmaceutical Co., Ltd selected site, Kumamoto

104-0045

Taiho Pharmaceutical Co., Ltd selected site, Tokyo

110-744

Taiho Pharmaceutical Co., Ltd selected site, Seoul

120-752

Taiho Pharmaceutical Co., Ltd selected site, Seoul

138-736

Taiho Pharmaceutical Co., Ltd selected site, Seoul

All Listed Sponsors
collaborator

Yakult Honsha Co., LTD

INDUSTRY

lead

Taiho Pharmaceutical Co., Ltd.

INDUSTRY

NCT02322593 - Phase III Study of TAS-118 Plus Oxaliplatin Versus S-1 Plus Cisplatin in Patients With Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter